Figure 3. Titre-dependent adverse effects following intra-SDH AAV2/5-gfaABC₁D injection.

(a) Immunofluorescence labelling for cell-type markers (GFAP, astrocytes; Iba1, microglia; NeuN, neurons) in the L4-SDH sections 28 days after intra-SDH injection of AAV2/5-gfaABC₁D-GFP (Scale bar, 200 μm). (b,c) mRNA expression of genes 28 days after intra-SDH injection of vehicle or rAAV (10¹¹–10¹³ GC/ml), and in naïve mice. Values represent the relative ratio of mRNA (normalized to Gapdh mRNA) to the mean expression level of mRNA in naïve mice. R, right; L, left (b,c; n = 6–8, ^***P < 0.001 versus naïve spinal cord). (d,e) mRNA expression of genes 14, 28 and 56 days after intra-SDH injection of rAAV (10¹² GC/ml) and in naïve mice. Values represent the relative ratio of mRNA (normalized to Gapdh mRNA) to the mean expression level of mRNA in naïve mice. (d,e; n = 6–8, ^**P < 0.01; ^***P < 0.001 versus naïve spinal cord). (f) Paw withdrawal threshold (PWT) of mechanical stimulation to the ipsilateral and contralateral hindpaws of vehicle and virus injected mice (10¹¹–10¹³ GC/ml) before (day 0) and after intra-SDH injection (n = 8; ^***P < 0.001 versus vehicle injected group).